-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
External T-cell lymphoma (PTCL) is susceptible to the unique influence of the ostogenesic genetic modification factor.
Lorenzo and others demonstrated synergy between hismoprotein deacetylase inhibitors and DNA methyl transferase inhibitors in in-body models of T-cell lymphoma.
in a Phase 1 trial, Lorenzo and others also found that oral 5-nitrogen cytosine (AZA) and romidesin (ROMI) were safely and effectively treated in patients with relapse/recurring (R/R) PTCL and had genealogical selective activity.
in this trial, patients with primary treatment (TN) or R/R PTCL were treated with AZA (300 mg/day, 1-14 days) and ROMOI (14 mg/m2, 8th, 15th and 22nd days) for 35 days/course of treatment.
objective indicator is the overall mitigation rate (ORR).
also targeted second-generation sequencing of tumor samples to analyze the correlation between mutation characteristics and therapeutic responses.
25 patients were recruited for the treatment response, with ORR and full remission rates of 61% and 48%, respectively.
patients with T-filter assist cell (tTFH) esotypes showed higher ORR (80%) and full remission rates (67%).
most common level 3-4 adverse reactions were thyroid reduction (48%), neutral granulocyte reduction (40%), lymphocyte reduction (32%) and anemia (16%).
13.5 months of time-dependent prognosm follow-up, with the medium PFS, DOR, and OS reaching 8.0 months, 20.3 months, and not reaching.
in the relapsed/refrmodynative patient substation, the medium PFS and OS were 8.0 months and 20.6 months, respectively.
survival was particularly longer (not achieved) in patients with tTFH.
the relationship between mutagenic cell mutations and therapeutic responses in patients with higher average numbers of mutations in genes associated with DNA methylation and histoprotein deacetylization.
AZA and ROMI in combination with PTCL patients to show good therapeutic results and can be used as a potential alternative to new therapies for the disease.
。
